Hyperion DeFi (HYPD) Registration Filing summary

Company overview and business model

• Operates as a digital ophthalmic technology company and builds a strategic treasury of Hyperliquid's native token, HYPE, providing exposure to the Hyperliquid blockchain ecosystem and developing the Optejet drug delivery device.

• Hyperliquid is a high-frequency, proof-of-stake blockchain supporting on-chain perpetual futures and smart contracts, with HYPE as its native token used for staking, governance, and transaction fees.

• Runs a co-branded Hyperliquid validator with Kinetiq, enabling direct access to staking yield and supporting network security, while also developing financial products leveraging HYPE's network benefits.

• The Optejet device delivers precise, low-volume ophthalmic medication, aiming for higher compliance and better patient outcomes compared to traditional eye drops.

Financial performance and metrics

• As of March 31, 2025, held $3.9 million in cash and cash equivalents and had an accumulated deficit of approximately $198.8 million.

• As of June 30, 2025, owed $8.2 million in principal and accrued interest under the Loan and Security Agreement.

• On June 20, 2025, raised approximately $50 million in gross proceeds from a private placement of Series A Preferred Stock and warrants.

Use of proceeds and capital allocation

• Proceeds from the private placement are allocated to building a reserve of HYPE tokens and implementing a HYPE staking program.

• Any proceeds from warrant exercises (up to $107.4 million if fully exercised) would be used for working capital, general corporate purposes, building the HYPE reserve, and debt repayment.